Table 3.
Characteristics of breakthrough infections among solid organ transplant recipients and matched controls.
| Breakthrough infection | SOT recipients (n=377)Median (IQR) or n (%) | Controls (n=773)Median (IQR) or n (%) | p-value |
|---|---|---|---|
| Total infections | 150 (40) | 301 (39) | 0.80 |
| Timing of infection | |||
| After first dose | 0/377 (0) | 1/773 (0.1) | >0.99 |
| After second dose | 3/377 (0.8) | 22/773 (2.9) | 0.03 |
| After third dose | 147/377 (39) | 278/773 (36) | 0.33 |
| Antibody concentration before infection | 123.5 (7.1-1059.7) |
23336.9 (4960.7- 46567.1) |
<0.001 |
| Variant | >0.99 | ||
| Delta | 7 (4.6) | 16 (5.3) | |
| Omicron | 134 (89) | 267 (89) | |
| Unknown | 9 (6) | 18 (6) | |
| Characteristics | |||
| Hospitalization | 13 (8.7) | Lacking data | |
| mAb treated | 58 (39) | Lacking data | |
| Death | 0 (0) | Lacking data | |
Variants were decided on dates concerning outbreak waves in Denmark.
Delta:1.6.2021-1.12.2021, Omicron: 21.12.2021-1.4.2022, Unknown: Outside given intervals.
mAb, monoclonal antibodies.